Heritability of variation in glycaemic response to metformin: A genome-wide complex trait analysis

The Lancet Diabetes and Endocrinology

Volumn 2, Issue 6, 2014, Pages 481-487

  Zhou, Kaixin ^a   Donnelly, Louise ^a   Yang, Jian ^b   Li, Miaoxin ^c   Deshmukh, Harshal ^a   Van Zuydam, Natalie ^d   Ahlqvist, Emma ^g   Spencer, Chris C ^f   Groop, Leif ^g   Morris, Andrew D ^a   Colhoun, Helen M ^a   Sham, Pak C ^c   McCarthy, Mark I ^d,e,f   Palmer, Colin N A ^a   Pearson, Ewan R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; METFORMIN; ANTIDIABETIC AGENT; GENETIC MARKER; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; DRUG RESPONSE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLYCEMIC RESPONSE; HERITABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PHARMACOLOGICAL PARAMETERS; PHENOTYPE; PRIORITY JOURNAL; BODY MASS; DIABETES MELLITUS, TYPE 2; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE BLOOD LEVEL; MIDDLE AGED; QUANTITATIVE TRAIT; SCOTLAND; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

BLOOD GLUCOSE; BODY MASS INDEX; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE TRAIT, HERITABLE; SCOTLAND;

EID: 84901638712     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(14)70050-6     Document Type: Article

References (22)

1. 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83-88. United Kingdom Prospective Diabetes Study (UKPDS).
2. DeFronzo RA, Goodman AM Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541-549.
3. Donnelly LA, Doney AS, Hattersley AT, Morris AD, Pearson ER The effect of obesity on glycaemic response to metformin or sulphonylureas in type 2 diabetes. Diabet Med 2006, 23:128-133.
4. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007, 117:1422-1431.
5. Song IS, Shin HJ, Shim EJ, et al. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin Pharmacol Ther 2008, 84:559-562.
6. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009, 58:745-749.
7. Jablonski KA, McAteer JB, de Bakker PI, et al. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010, 59:2672-2681. for the Diabetes Prevention Program Research Group.
8. The Wellcome Trust Case Control Consortium 2. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011, 43:117-120. The GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group.
9. So HC, Li M, Sham PC Uncovering the total heritability explained by all true susceptibility variants in a genome-wide association study. Genet Epidemiol 2011, 35:447-456.
10. Yang J, Manolio TA, Pasquale LR, et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet 2011, 43:519-525.
11. Zhou X, Stephens M Genome-wide efficient mixed-model analysis for association studies. Nat Genet 2012, 44:821-824.
12. Wray NR, Yang J, Hayes BJ, Price AL, Goddard ME, Visscher PM Pitfalls of predicting complex traits from SNPs. Nat Rev Genet 2013, 14:507-515.
13. Yang J, Lee SH, Goddard ME, Visscher PM GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 2011, 88:76-82.
14. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007, 56:2178-2182.
15. Yang J, Benyamin B, McEvoy BP, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet 2010, 42:565-569.
16. Lee SH, DeCandia TR, Ripke S, et al. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet 2012, 44:247-250.
17. Lee SH, Harold D, Nyholt DR, et al. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Hum Mol Genet 2013, 22:832-841.
18. 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 2010, 27:309-317.
19. Barber MJ, Mangravite LM, Hyde CL, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS One 2010, 5:e9763.
20. Mangravite LM, Engelhardt BE, Medina MW, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013, 502:377-380.
21. Hopewell JC, Parish S, Offer A, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. Eur Heart J 2013, 34:982-992. for the MRC/BHF Heart Protection Study Collaborative Group.
22. Hemani G, Yang J GCTA-GREML Power Calculator (accessed Feb 14, 2014). http://spark.rstudio.com/ctgg/gctaPower/.